Jiao Hong: encourage innovation, strictly supervise and promote the development of pharmaceutical industry

Source: medical economics journal Author: Liu Zhengwu, November 23, 2016, "innovation momentum is surging" Jiao Hong, deputy director of the State Food and drug administration, attended the 28th national pharmaceutical economic information conference held in Guangzhou He pointed out that promoting the innovation and development of the pharmaceutical industry is of great significance to better meet the medical and health care needs of the masses and promote the construction of a healthy China It is also an important aspect of supply side structural reform Jiao Hong, deputy director of the State Food and drug administration, developed rapidly in the pharmaceutical industry during the 12th Five Year Plan Jiao Hong said that the pharmaceutical industry is an important foundation for supporting the development of medical and health services and a sunrise industry with strong growth and driving force In recent years, China's pharmaceutical industry has developed rapidly During the 12th Five Year Plan period, the compound annual growth rate of China's pharmaceutical market reached 14.3%, while the compound annual growth rate of the world's pharmaceutical market was 5.0% From January to September 2016, the added value of China's pharmaceutical industry above designated size increased by 10.4% year on year, higher than the overall growth rate of the industry Jiao Hong pointed out that drug and food safety is directly related to the vital interests of the people The CPC Central Committee and the State Council attach great importance to this work, which is emphasized at the highest political level and deployed at the level related to public safety Recently, the Sixth Plenary Session of the 18th Central Committee emphasized the construction of food and drug safety management system, the reform of drug and medical device review and approval system, and the reform of drug circulation system The State Food and Drug Administration (hereinafter referred to as the General Administration) conscientiously implements the decision-making and deployment of the Party Central Committee and the State Council, in accordance with the "four strictest" We will improve the regulations and standard system of medical devices, strengthen the whole process supervision, strengthen the management of clinical trials, increase the intensity of flight inspection and overseas inspection, further improve the supervision system covering the whole process of development, production, circulation and use, and improve the safety guarantee ability and risk control level of medical devices Focusing on the theme of innovation in China's pharmaceutical industry, Jiao Hong stressed that encouraging innovation is also the key work actively promoted by the general administration In recent two years, the General Administration has implemented the key tasks of the central government on comprehensively deepening the reform, deeply implemented the innovation driven development strategy, and vigorously promoted the reform of the drug and medical device review and approval system The reform focuses on improving the quality and efficiency of review and approval, optimizing the review and approval mechanism, and constantly improving the scientific level of review and approval At the same time, the General Administration issued a series of policies and measures to promote the R & D and application of new products and technologies, accelerate the review and approval of clinical urgently needed products, and a batch of innovative products entered the market through the green channel of examination and approval, so as to better meet the needs of the public for drugs and equipment To jointly promote the industrial innovation and development, Jiao Hong stressed that pharmaceutical production and operation enterprises are the main body to ensure quality and safety Enterprises should strictly abide by laws and regulations, strengthen management in accordance with production and operation quality management standards, strengthen industry self-discipline, jointly create a market environment of honesty and trustworthiness, and build a good pattern of social co governance Jiao Hong said that as a pharmaceutical policy and industrial economic research institution directly under the General Administration of the people's Republic of China, Nanfang Institute has, over the years, given full play to the advantages of information and media services, conducted in-depth research on the laws and trends of China's pharmaceutical economic development, and provided important services for the overall regulatory situation and industrial development The national pharmaceutical economic information conference guided by Nanfang Institute and hosted by the pharmaceutical economic newspaper has become a good platform for publishing industry research data, publicizing pharmaceutical policies and information exchange for many years I hope that through this platform, you can have in-depth exchanges, gather wisdom, jointly promote innovation and development of the pharmaceutical industry, and better benefit public health!